NCT01239342: A reported trial by National Cancer Institute (NCI)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01239342 |
|---|---|
| Title | A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 27, 2011 |
| Completion date | Sept. 19, 2018 |
| Required reporting date | Sept. 19, 2019, midnight |
| Actual reporting date | March 22, 2017 |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | None |